139 results about "Mice brain" patented technology

The invention relates to bifidobacterium breve CCFM1025, a fermented food and application thereof. The bifidobacterium breve CCFM1025 can be used for improving the depression-like behavior of a depression mouse, improving 5-hydroxytryptamine in the brain of the depression mouse, improving the level of 5-hydroxytryptamine and a brain-derived neurotrophic factor, reducing the level of corticosteronein serum of the depression mouse, improving the level of 5-hydroxytryptamine in the serum of the depression mouse, improving intestinal flora disturbance of the depression mouse, reducing the abundance of intestinal veillonella, improving the abundance of bifidobacterium and mycoplasmataceae, improving alpha-diversity of intestinal flora and reducing occurrence of inflammatory bowel disease and obesity. By adopting the bifidobacterium breve CCFM1025, the mRNA level of tryptophan hydroxylase in a simulated entero-chromaffin cell can be improved, the secretion volume of 5-hydroxytryptophane ofthe cell can be improved, and a precursor substance is specifically provided to synthesis of 5-hydroxytryptamine in the brain. The bifidobacterium breve CCFM1025 has a wide application prospect.

The invention discloses a PEGylated scutellarin compound and a preparation method thereof. The PEGylated scutellarin compound is as the shown formula (IV) and the PEGylated scutellarin compound can be applied to preparing medicaments applied to treating cerebral thrombosis, cerebral infarction, cerebral apoplexy, sequelaes caused by cerebral apoplexy, coronary heart disease or angina. Compared with the original scutellarin compound, the water solubility of the scutellarin compound is increased obviously; simultaneously, pharmacodynamics experiment on the mice model of cerebral ischemia-reperfusion shows that: compared with the original medicament, the biological activity of the scutellarin promedicament is strengthened obviously.

The present invention relates to bifidobacterium breve CCFM1025, its fermented food and application thereof. Bifidobacterium breve CCFM1025 of the present invention can improve the depression-like behavior of depressed mice, increase the levels of 5-hydroxytryptophan, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice, and reduce the levels of 5-hydroxytryptophan in the serum of depressed mice. Corticosterone levels, increased serum 5-hydroxytryptamine levels in depressed mice, improved intestinal flora disturbance in depressed mice, decreased intestinal Veillonellaceae abundance, increased the abundance of Bifidobacteria and Mycoplasmaceae , increase the α-diversity of intestinal flora, reduce the occurrence of inflammatory bowel disease and obesity; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the level of 5-hydroxytryptophan in this cell Secretion, specifically providing precursors for the synthesis of 5-HT in the brain. It has broad application prospects.

The present invention is one kind of red peony injection prepared with red peony root as material and through alcohol extraction, n-butanol extraction or macroporous resin purification, and adding proper amount of medicinal supplementary material and injection water. It is stable and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic experiment shows that the medicine of the present invention can improve the behavior disorder of rat with cerebral infarction obviously, reduce the area of cerebral infarction, decrease water content in infracted brain tissue, reduce the peroxidation damage of lipoid in brain tissue and raise the acute oxygen lack tolerance of mouse and thus has excellent treat effect on cerebral infarction.

The invention relates to bifidobacterium longum subspecies CCFM687, fermented food and application thereof. Bifidobacterium longum infantile subspecies CCFM687 of the present invention can improve the depression-like behavior of depressed mice, improve the levels of 5-hydroxytryptamine, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice; improve depression Butyric acid content in the gut of mice; lower intestinal abundance of Desulfovibrio spp., increased abundance of Bifidobacterium and S24‑7 families, increased gut microbiota α‑diversity, and improved intestinal Intestinal flora disorder, reduce the occurrence of autism, inflammatory bowel disease, obesity and type I diabetes; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the 5-hydroxychromatin level of the cells The secretion of amino acid provides precursor substances for the synthesis of 5-hydroxytryptamine in the brain. Therefore, it has broad application value.

The invention provides a preparation method and application of a PQQ-DA imprinted magnetic nanoparticle, belonging to the field of bioanalysis technology. According to the preparation method, Fe3O4 is used as a core and coated with SiO2; then preparation is carried out so as to obtain the PQQ-DA imprinted magnetic nanoparticle; thus, a PQQ-DA magnetic nanoparticle imprinted material with high recognizability and high selectivity on its surface. After molecular imprinting modification of a magnetic nanoparticle with specificity, the prepared imprinted magnetic nanoparticle has magnetism and specific selectivity to targets and is greatly advantaged in separation, purification and enrichment of medium-and-low-concentration compounds in brain tissue of a complex matrix. The prepared PQQ-DA imprinted magnetic nanoparticle is applied to UPLC-MS determination for analysis of trace PQQ-DA in an organism. According to the invention, UPLC-MS based on molecularly-imprinted solid-phase extraction is established in the invention, can detect the content of trace PQQ-DA in the brain of a mouse and has a detection limit of 0.2 * 10<-11> mg / mL. The PQQ-DA imprinted magnetic nanoparticle has great guidance significance to research on the occurrence and mechanism of neurological diseases.

The invention discloses an application of ganoderic acid A to preparation of drugs for activating brain CD4+T cells and inhibiting neuroinflammation. Experiments show that the ganoderic acid A significantly up-regulates the content of CD4+T in mouse brains, reduces the levels of L-1beta, IL-6, TNF-alpha, NF-kB and the like, and down-regulates expression of Abeta1-42, p-Tau, APOE, IBA-1, and GFAP,which suggests that the ganoderic acid A can activate the CD4+T cells in brains and inhibit neuroinflammation. Acute toxicity experiments on cells and animals show that the safe dose range of the ganoderic acid A is wide, and can be applied to preparation of the drugs for activating the CD4+T cells in brains and inhibiting neuroinflammation.

Comprehensive analysis of transcription control factor complexes in a mouse brain cDNA library with c-Jun as a bait by using the cotranslation selection and screening of in vitro virus (IVV) and the C-terminal labeling method are conducted, thereby to provide known and unknown proteins which are unknown to form a complex with the c-Jun protein, whereby proteins that interact with c-Jun, nucleic acids encoding them and inhibitors utilizing them as well as methods for detecting an interaction and screening methods are provided.

The invention relates to a sample preparation method for mice brain tissue proteome analysis. The method comprises the following steps: (1) replacing the blood through apex perfusion, namely, narcotizing a mice, performing slow apex perfusion, stopping while the liver is in grey white, and taking out a brain tissue; (2) extracting protein, namely, grinding the brain tissue into powder, adding a pre-cooled Tris buffer solution, ultrasonically treating, incubating in a shaking table, and centrifuging to obtain a protein extracting solution I; (3) thermally treating to increase protein solubility, namely, mixing the protein extracting solution I and the thermally treated solution, treating for 5min, and centrifuging to obtain the protein extracting solution II; (4) precipitating to remove fat, namely, adding the protein extracting solution II in the pre-cooled fat-removing precipitation solution CUS, precipitating, centrifuging, washing, and drying to obtain purified protein powder; and (5) re-dissolving the protein, namely, adding the purified protein powder in an urea protein lysate, and centrifuging to obtain a proteome sample. With the sample preparation method disclosed by the invention, blood and fat influences of the brain tissue of the mice can be economically and efficiently removed, and the solubility of the protein sample is increased.

The invention provides a chemical heredity epilepsy persistent state disease animal model and a construction method and application thereof. The epilepsy persistent state disease animal model is a mouse brain kernel group (a hippocampus CA1 region and a thalamus anterior nucleus VA region of a model I); injecting a brain stereotaxic virus (a chemical genetic virus rAAV-CaMKIIa-hM3D (Gq)-mCherry-WPREs-pA) in an apricot kernel BLA region and a thalamus anterior nucleus VA region on the outer side of a substrate of the model II, and embedding an electrode array in a mouse hippocampus CA3 region;after the mouse is recovered for one week, a metabolite CNO of clozapine is injected into the abdominal cavity so that the CNO is combined with a virus expression receptor, neurons are activated to induce epileptic persistent state attack, and the epilepsy persistent state disease animal model is obtained through behavioral observation and in-vivo multichannel local field potential recording judgment. The epilepsy persistent state disease animal model constructed by the method is stable in seizure duration, high in success rate, low in death rate and good in repeatability, and has important significance in researching the origin and formation mechanism of epilepsy persistent state, and screening and mechanism of drug-resistant epilepsy persistent state drugs.

The invention provides a double-color fluorescent probe as well as a synthesis method and application thereof, the double-color fluorescent probe is especially suitable for simultaneously detecting O2. <-> and Zn < 2 + > in a living body, the double-color fluorescent probe is composed of dipyridylmethylamine(DPA), caffeic acid and 4-bromo-1, 8-naphthoic anhydride, the double-color fluorescent probe has the advantages of simple preparation, sensitive detection, good selectivity and the like. According to the method, the change of the O2. <-> and Zn < 2 + > in the brain of the mouse with depression is successfully imaged and analyzed at the living body level for the first time, and the method has good practical application value.

The invention relates to a medicinal composition, in particular to a composition comprising 4-hydroxyl-2-oxo-1-pyrrolidine acetamine and 2-borneol, and application of the composition in medicines for preventing and / or treating cognition impairment. The composition provided by the invention can remarkably improve a cerebral trauma neural function of a rat and can remarkably prolong the time of passive activities. The composition provided by the invention plays a role in improving dysmnesia of the rat, caused by scopolamine, and can remarkably improve cognitive disorder of the rat, caused by cerebral ischemia. The composition has a remarkable effect in preventing and / or treating cognition impairment.

The invention belongs to the field of biotechnology and cerebral arterial thrombosis, and particularly relates to application of circular RNA circ-FoxO3 in preparation of products for preventing and treating cerebral arterial thrombosis. The circular RNA is highly conservative and has the same reverse shearing site in human-derived or mouse-derived species. The application proves that the circ-FoxO3 is highly expressed in cerebrovascular endothelial cells of a MCAO / R mouse and the cerebrovascular endothelial cell line subjected to OGD / R treatment; A certain effect of the circ-FoxO3 in the endothelial barrier treated by OGD / R is shown by knockdown or over-expression of the circFoxO3. The application of the circular RNA circ-FoxO3 provides a new thought for prevention of hemorrhagic transformation after acute ischemic stroke, and provides a new target for development of a neurovascular protective agent.

The invention relates to a medicine for preventing and treating ischemic stroke. In the mouse cerebral ischemia-reperfusion model, the compound of the present invention can significantly reduce the behavioral score, can significantly reduce the percentage of cerebral infarction / whole brain, and can significantly reduce the water content of ischemia-reperfusion damaged brain tissue, and relieve ischemia. The degree of lateral cerebral hemisphere edema can be used to prevent and treat ischemic stroke.

The invention discloses bifidobacterium lactis Probio-M8 capable of relieving and improving symptoms of Alzheimer's diseases and applications thereof. APP / PS1 mice are taken as experimental subjects;7 mice whose genotypes are APP / PS1 are selected from the mice delivered through paired reproduction with wild mice; and after the random dividing of the mice into two groups, the bifidobacterium lactis Probio-M8 is poured into the stomach of the mice in one group, and normal saline is poured into the stomach of the mice in the other group, so that the changing of the number of A[beta] plaques in the brains of the mice can be determined. Through the proving of experimental results, the bifidobacterium lactis Probio-M8 has the effects of relieving and improving the symptoms of Alzheimer's diseases.

The invention relates to the field of gene engineering, and in particular relates to new LGI 1 gene mutation causing temporal lobe epilepsy (TLE) newly found in people and an application. The invention discloses the application of the 152nd gene locus A152G mutation of a first exon of an LGI 1 gene in preparation of a temporal lobe epilepsy co-disease depression animal model, and the application in screening of anti-temporal lobe epilepsy co-disease depression drugs. According to the invention, a homozygous model mouse with the gene mutation shows lethal epilepsy; an electroencephalogram of the heterozygous mouse can record epilepsy waveforms, and behavioristics shows that the mouse has co-disease depression; and the mouse can serve as new animal model of epilepsy co-disease depression andis used for mechanism research of epilepsy attack and epilepsy co-disease depression and research and development of anti-epilepsy combined depression drugs.

The invention belongs to the field of biological products, and relates to a composite vaccine for Alzheimer's disease prevention and treatment, wherein the composite vaccine is prepared by mixing a nucleic acid vaccine encoding Abeta42 and a protein gene engineering vaccine. Experiment results show that: Abeta42 protein antigen expressed through prokaryotic expression and pVAX-Abeta42 plasmid are adopted to co-immunize, such that the Alzheimer's disease protein vaccine in the prior art is improved, high level anti-Abeta antibody IgG can be produced, inhibition on T cell response can be induced, and the inhibition can be maintained for a fairly long time. In addition, the antibody generated through co-immunizing and for Abeta can be combined with Abeta protein fibers and nature Abeta protein precipitate in APP / PS1 Alzheimer's disease transgene incidence mice brain so as to provide Abeta precipitate removing capacity; and the vaccine is a potential, effective, and side effect-free vaccine, and can be used for Alzheimer's disease prevention and treatment.

The invention discloses a large and small mouse stereotaxic apparatus fixing structure, which comprises an operating plate, wherein the operating plate is connected with a fixing column through a regulation mechanism; the fixing column is provided with a tooth fixing mechanism; and the top of the operating plate is fixedly connected with two symmetrical fixing blocks a. The large and small mouse stereotaxic apparatus fixing structure has high regulation accuracy, and in a process that a large and small mouse is fixed, a situation that the teeth bleed or the eardrum is broken due to improper regulation can be avoided. The top of a supporting plate is provided with a magnet a and a magnet b so as to realize an effect that tissues or cloth liners can be conveniently fixed, and a situation that in a process that the large and small mouse receives a test, the large and small mouse suffers from gatism to pollute the supporting plate is avoided. The height of the supporting plate can be improved and reduced according to requirements so as to quickly fix the large and small mouse by an ear rod and a tooth fixing rod, and test efficiency is improved.

The invention relates to an experimental animal fixing device, in particular to a fixing device for mouse brain electrophotoluminescence in the waking state. The fixing device comprises a fixing cover, a fixing belt and a fixing mechanism. The fixing mechanism comprises a fixing panel, a fixing piece, a rotatable rod and fixing hook nails. The fixing piece is arranged on the fixing panel. The rotatable rod is fixed to the fixing panel through the fixing piece. The hook nails are arranged on the two side faces of the fixing panel. An arc fixing opening is formed in the middle of the rotatable rod. The fixing cover is arranged on the fixing panel. The fixing belt is bound on the fixing hook nails to fix the fixing panel and the fixing cover. The mouse fixing device is simple in structure, convenient to assemble, easy to operate, low in cost, convenient to manufacture and capable of effectively fixing a mouse when the mouse is kept in the waking state; the fixing cover, the fixing mechanism, the fixing belt and the base are detachable and easy to clean and disinfect.

The invention discloses a breeding method of rabies virus attenuated strains; the method comprises the following steps: using a CTN-181 strain homologous with a strain CTN-1-V for the production of rabies vaccine for Chinese people as a parent strain, and cloning and screening by virtue of in vitro cell line culture, animal in vivo tissue alternate passage and a plaque purification technology; screening neurovirulence in the brains of mice at different day ages so as to obtain two attenuated strains which are respectively named as CTN-1-3 and CTN-1-19; and carrying out amplification, titration, verification and whole genome sequencing to the attenuated strains so as to obtain a CTN-1-3 whole genome sequence as shown in SEQ ID NO:1 and a CTN-1-19 whole genome sequence as shown in SEQ ID NO:2. The attenuated strains disclosed by the invention are low in strain residual virulence, good in immunogenicity and good in genetic stability; the strains have reached or exceeded requirements of World Health Organization (WHO) on the safety and the validity of candidate strains; and the strains are suitable for producing oral live vaccine for rabies.

The invention provides a near-infrared A beta fluorescence imaging agent with high signal-noise ratio, as well as a preparation method and application thereof. An aggregation-induced emission dye hasa structure as shown in the formula I. In addition, the invention also provides application of the A beta fluorescence imaging agent in brain tissue slice fluorescent marking and living imaging. The tests show that the aggregation-induced emission dye provided by the invention has the advantages of near-infrared emission, high light stability, good biocompatibility, high signal-noise ratio and thelike, and can be used for accurately positioning an A beta plaque in an APP / PS1 transgenic mice brain tissue slice, so that the in-situ information such as the number of A beta plaques and real-timeform is acquired in a high fidelity way. Particularly, the imaging agent has favorable blood-brain barrier penetrability, and can be applied to in-vivo real-time imaging of the APP / PS1 transgenic micebrain A beta plaque. The formula I is shown in the description.

The present invention relates to a compound for preventing and treating cerebral apoplexy, particularly ischemic cerebral apoplexy, wherein the compound exhibits good therapeutic activity in a mouse cerebral ischemia reperfusion test, can significantly reduce the proportion of cerebral infarction, and can be used for preventing and treating cerebral apoplexy, particularly ischemic cerebral apoplexy.

The invention discloses a preparation method of an adult stem cell exosome and application thereof to treatment of Parkinson's disease, and belongs to the technical field of biomedicine. The preparation method comprises the steps that bone marrow mesenchymal stem cells, skin epidermis stem cells and adipose-derived stem cells are separated and cultured in vitro, exosomes in cell culture supernatants are extracted by an ultracentrifugation method, and the exosomes are administered by a nasal administration mode. The exosomes from the three sources can significantly relieve related symptoms of Parkinson's disease model mice, such as recovery of movement functions of the mice and increase of the number of dopaminergic neuronal cells at the black part in the brains of the mice.

The invention discloses an enzymatic hydrolysate suitable for mouse brain tissue cell separation in any period and an optimization method for realizing low loss of a single-cell suspension. The proportion of living cells in the single-cell suspension obtained by the method is superior to that of the single-cell suspension obtained by the method in the prior art. Due to the advantages, technicians in the field can complete separation of brain tissue cells of mice in all stages and obtain cell suspension with high motility rate, high yield and low impurity ratio, or the separated cells can be continuously applied to subsequent single cell sequencing experiments, and a more real and meaningful result is obtained. And a more complete guarantee is provided for further clarification of disease mechanisms and treatment of diseases.

The invention provides a mouse Shank 3 gene cRNA probe and an in-situ hybridization color development method. The cRNA probe comprises a nucleotide sequence with complementary sites 3465-4108 of a reference sequence NM_021423.3 of mouse Shank 3 gene mRNA. The in-situ hybridization color development method comprises the following steps: putting a mouse brain tissue sample in a hybridization solution; after hybridization, rinsing, closing and combining with an antibody; amplifying with TSA-biotin and performing fluorescent color development. The cRNA probe provided by the invention has high specificity on the Shank 3 gene, can efficiently finish recognition of the Shank 3 gene in the brain tissues of different individuals, can ensure the specificity and high efficiency of in-situ hybridization color development of the mouse Shank 3 gene, realizes a better color development effect and can be combined with other hybridization or immunofluorescent staining.

The invention belongs to the technical field of pharmacy, and particularly relates to an application of danshinolic acid A in preparation of medicines for preventing and treating AIDS encephalopathy as well as nerve damages caused by an HIV-1Tat protein. According to the invention, an HIV-1Tat protein damage type nerve cell line PC 12 and nerve cells on mouse brain slices are protected by using danshinolic acid A with different concentrations, and the effect of reducing the death of the nerve cells caused by the Tat protein of the danshinolic acid A is respectively detected by an MTT experiment, LDH detection and a Tunnel experiment; and dendritic spines are labeled by scattering Dil gold particles, and the effect of reducing Tat protein damage synaptic connectivity of the danshinolic acid A is detected. Through statistical analysis of experimental results, the danshinolic acid A is found to have a good protection effect against damages of the nerve cells caused by the Tat protein and can be used for preparing the medicines for preventing and treating the nerve damages caused by the Tat protein as well as the AIDS encephalopathy.

The invention discloses a novel application of red stilbene and red stilbene polysaccharide in preparing medicament for treatment of Alzheimer disease. Red stibene and red stilbene polysaccharide in the invention can protect SH-SY5Y cells from the damage from A beta 25-35, and increase the viability of SH-SY5Y cells. The Morris water maze test indicates that red stibene and red stilbene polysaccharide can improve the cognitive dysfunction of mice with rapid brain aging and rats injected with A beta and AD in the hippocampus. Further histology detection indicates that red stilbene and red stilbene polysaccharide can increase the contents of center neurotransmitters 5-HT, 5-HIAA, NE and DA in rapid aging mice brain, wherein the neurotransmitters are monoamines.

The invention discloses an administration method for an experimental animal brain; by adopting a method for burying a catheter into the experimental animal brain, injection to the experimental animal brain is more convenient. According to the administration method, a special successive administration device is adopted, and a mouse or a rat is taken as an experimental animal, and the administration method comprises the following steps: 1, narcotizing the experimental animal with 30 percent of chloral hydrate, fixing the experimental animal on a mouse brain locator, and determining the position of a paracele; 2, burying an administration catheter into the paracele of the experimental animal according to the step, and fixing the catheter to the head of the experimental animal by dental cement when cerebrospinal fluid overflows from the catheter; 3, in 4 days after the catheter is buried successfully, performing successive intramuscular injection every day with 0.2ml of 0.8 million units of penicillin sodium, and diminishing inflammation of the experimental animal; 4, performing administration: sucking up a right amount of to-be-experimented drug solution by a 10mul microinjector, and partially inserting the syringe needle of a microsyringe into the catheter buried into the experimental animal brain, wherein the insertion depth is 0.5-2.0cm, and successive administration can be performed on the mice brain from the catheter.

The invention discloses an application of Hispolon in the improvement of the cognition and memory ability and the reduction of senile plaques. Alzheimer's disease (AD) is a neurodegenerative disease with nerve cell fiber entanglement, amyloid beta-protein (Abeta) plaque deposition and cognition function decline as pathologic characteristics, wherein Abeta extracellular toxic accumulation is considered as one of main attack links of the AD. It is found that the Hispolon can improve the spatial memory learning ability of AD mice and obviously clear amyloid plaques in APP / PS1 double transgenic ADmodel mice brain tissues, which shows that the Hispolon can be applied to the treatment of the AD and the development of related drugs.

The invention which relates to the biomedicine field discloses a mechanical separation method of neurons of adult mice. The method comprises the following steps: making the adult mice's brain tissue slices with the thickness of 350-375mum in an ice bath tissue culture solution with an electronic vibration slicer, preserving for 30-60min at room temperature, putting the brain tissue slices into a papain-containing tissue culture solution under aseptic conditions, controlling the temperature at 32.2-35.3DEG C, maintaining the temperature for 30min, placing the brain slices in a cell culture dish containing an HEPES buffer solution, selecting a neural region needing separation, and separating neurons through using a cell separator; and screening healthy neurons. The method of the invention, which allows a primary culture chemical separation method to be integrated into mechanical cell separation and the brain slices to be preprocessed with the papain, makes the healthy neurons of adult and aged mice to be obtained through the mechanical separation, and has the advantages of simplicity, convenience, and substantial separation effect.